tyriandiagnostics

22 December 2010

ASX Limited
20 Bridge Street
Sydney NSW 2000

Attention: Company Announcements Office

Dear Sir/ Madam,

Replacement Appendix 3B

Attached is an Appendix 3B in respect of the Rights Issue recently concluded by Tyrian Diagnostics Limited (**Tyrian**), which replaces the Appendix 3B lodged on 18 November 2010. The replacement Appendix 3B is required to update the following details in the original document:

- Actual number of shares issued is 496,516,341 (change from 498,516,341 estimated in original document, difference due to an application for shares for one investor being invalidated after the close of the offer)

- Actual number of options issued 199,006,544 (change from 199,406,536 estimated in original document, difference due an application for shares for one investor being invalidated after the close of the offer and rounding)

- Amount of underwriter's fee and commission is $198,606 plus 99,703,268 options expiring on 20 December 2013 (change of commission from $199,406 estimated in original document, difference due an application for shares for one investor being invalidated after the close of the offer)

- Securities allotted and certificates despatched 22 December 2010 (21 December 2010 estimated in original document).

Yours sincerely

Michael Vamos
Assistant Company secretary

1/35-41 Waterloo Road, North Ryde NSW 2113 Australia
t +61 2 9889 1830 f +61 2 9889 1805 www.tyriandx.com
Tyrian Diagnostics Limited ABN 56 080 277 998

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

TYRIAN DIAGNOSTICS LIMITED

ABN

56 080 277 998

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	ORDINARY SHARES OPTIONS
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	ORDINARY SHARES: 496,516,341 OPTIONS: 199,006,544
3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	(a) Fully paid ordinary shares (b) Options with an exercise price of $0.012 expiring on 20 December 2013

+ See chapter 19 for defined terms.

4	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	(a) Yes. Ordinary shares will rank equally with existing ordinary shares. (b) Options will not rank equally with any existing class of quoted securities. Shares issued upon exercise of the options will rank equally with existing ordinary shares
5	Issue price or consideration	ORDINARY SHARES: $0.008 OPTIONS: Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To provide additional funding to expand the Company's diagnostic product portfolio for agriculture and to advance development of its first sputum based diagnostic for chronic respiratory disease using its DiagnostIQ™ test platform and for working capital.
7	Dates of entering +securities into uncertificated holdings or despatch of certificates	22 December 2010

8 Number and +class of all +securities quoted on ASX (*including* the securities in clause 2 if applicable)

Number	+Class
995,032,682	Ordinary Shares
199,006,544	Options

+ See chapter 19 for defined terms.

		Number	+Class
9	Number and +class of all +securities not quoted on ASX (*including* the securities in clause 2 if applicable)	62,207,286	Unlisted Options with an exercise price of $0.03 expiring 31 December 2010
		11,139,334	Performance Rights under the Company's Performance Rights Share Plan

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	No
12	Is the issue renounceable or non-renounceable?	Non-renounceable
13	Ratio in which the +securities will be offered	1 new share for every share held and one attaching option for every five new shares subscribed for.
14	+Class of +securities to which the offer relates	(a) Ordinary fully paid shares (b) Options to acquire ordinary fully paid shares
15	+Record date to determine entitlements	7:00pm (Sydney time), 26th November 2010
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	Fractional entitlements will be rounded up to the nearest whole number of shares or options

+ See chapter 19 for defined terms.

18	Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	France; Indonesia; Italy; Japan; Singapore; Switzerland; United Kingdom; and United States, other than shareholders in those jurisdictions who can demonstarte to the company that it would nto be unlawful to make the offer.
19	Closing date for receipt of acceptances or renunciations	13 December 2010
20	Names of any underwriters	Patersons Securities Limited
21	Amount of any underwriting fee or commission	$198,606 plus 99,703,268 options to acquire ordinary shares at an exercise price of 1.2cents expiring 20 December 2013
22	Names of any brokers to the issue	Patersons Securities Limited
23	Fee or commission payable to the broker to the issue	$60,000
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	29 November 2010
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	18 November 2010

+ See chapter 19 for defined terms.

28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do +security holders sell their entitlements *in full* through a broker?	N/A
31	How do +security holders sell *part* of their entitlements through a broker and accept for the balance?	N/A
32	How do +security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	+Despatch date	22 December 2010

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(*tick one*)

(a) ☑ Securities described in Part 1

☐

(b) ☐ All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

+ See chapter 19 for defined terms.

35 ☐ If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 ☐ If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 ☐ A copy of any trust deed for the additional +securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of securities for which +quotation is sought	
39	Class of +securities for which quotation is sought	
40	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)	

42 Number and +class of all +securities quoted on ASX (*including* the securities in clause 38)

Number	+Class

+ See chapter 19 for defined terms.

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

- There is no reason why those +securities should not be granted +quotation.

- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

  Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: .... Date: .22 December 2010
(~~Director~~/Company secretary)

Print name: .Michael Stuart Vamos...................

== == == == ==

+ See chapter 19 for defined terms.